FDA turns attention to data integrity lapses at testing sites in new guidance
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyCompliancePharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyUnited States